imatinib mesylate has been researched along with Carcinoma, Small Cell Lung in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baek, EJ; Kim, JO; Kim, KH; Ko, BJ; Ko, HJ; Park, B; Park, SG; So, MK | 1 |
| de Lima, MC; Moreira, JN; Santos, A; Sarmento-Ribeiro, AB; Simões, S | 1 |
| Cordier, JF; Cottin, V; Girard, N; Lapalus, MG; Tronc, F | 1 |
| Igishi, T; Kodani, M; Matsumoto, S; Matsunami, K; Morita, M; Nakazaki, H; Shigeoka, Y; Shimizu, E; Sumikawa, T; Suyama, H; Takeda, K; Ueda, Y | 1 |
| Chen, W; Gadgeel, SM; Kalemkerian, GP; Kraut, MJ; Ramnath, N; Ruckdeschel, JC; Schneider, BJ; Worden, FP; Wozniak, AJ; Zhang, X | 1 |
1 trial(s) available for imatinib mesylate and Carcinoma, Small Cell Lung
| Article | Year |
|---|---|
Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2010 |
4 other study(ies) available for imatinib mesylate and Carcinoma, Small Cell Lung
| Article | Year |
|---|---|
A novel anti-c-Kit antibody-drug conjugate to treat wild-type and activating-mutant c-Kit-positive tumors.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoconjugates; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2022 |
Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer.
Topics: Annexin A5; Antineoplastic Agents; Benzamides; Cell Survival; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Small Cell Lung Carcinoma | 2008 |
Synchronous small-cell lung cancer and gastrointestinal stromal tumor: a case report.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Doxorubicin; Etoposide; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Ifosfamide; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Palliative Care; Piperazines; Pyrimidines; Small Cell Lung Carcinoma; Stomach Neoplasms | 2009 |
Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
Topics: Anthracyclines; Benzamides; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Imatinib Mesylate; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; Small Cell Lung Carcinoma; Tetrazolium Salts; Thiazoles | 2010 |